Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Epstein-Barr Virus
100%
Precancerous Lesions
100%
DNA Damage
100%
Co-expression
100%
Low-risk Human Papillomavirus
100%
Latent Membrane Protein 1 (LMP1)
100%
Low Risk
33%
HPV6
33%
Anchorage-independent Growth
25%
DNA Damage Response
16%
NF-B
16%
Matrix metalloproteinase-2 (MMP-2)
16%
Paxillin
16%
Oral Carcinogenesis
16%
Tissue Sampling
8%
Signaling Pathway
8%
Mouse Embryonic Fibroblasts
8%
Cell Proliferation
8%
Oral Cancer
8%
High Risk
8%
Signaling Molecules
8%
Apoptosis
8%
High-risk Human Papillomavirus (HR-HPV)
8%
E7 Gene
8%
Cancer Tissue
8%
HPV11
8%
Invasiveness
8%
P53 Activity
8%
Co-infection
8%
HPV16 E7
8%
Apoptosis Inhibition
8%
Malignant Transformation
8%
Adhesion Signaling
8%
Somatic mutation
8%
Malignant Characteristics
8%
Oral Cells
8%
DNA Damage Tolerance
8%
Medicine and Dentistry
Epstein Barr Virus
100%
Precancerous Condition
100%
DNA Damage
100%
Wart Virus
100%
Carcinogenesis
41%
Human Papillomavirus Type 6
33%
Anchorage Independent Growth
25%
Cell Line
16%
Infection
16%
Protein P53
16%
Programmed Cell Death
16%
DNA Damage Response
16%
Gelatinase A
16%
Paxillin
16%
Cell Signaling Pathway
8%
Cell Proliferation
8%
Oral Cancer
8%
Mixed Infection
8%
Human Papillomavirus Type 16
8%
Human Papillomavirus Type 11
8%
Signaling Molecule
8%
Cancer Tissue
8%
Somatic Mutation
8%
Malignant Transformation
8%
Fibroblast
8%
Immunology and Microbiology
Wart Virus
100%
DNA Damage
100%
Epstein Barr Virus
100%
Human Papillomavirus Type 6
33%
Anchorage Independent Growth
25%
Cell Line
16%
P53
16%
Nude Mouse
16%
DNA Damage Response
16%
Programmed Cell Death
16%
Cell Proliferation
8%
Coinfection
8%
Human Papillomavirus Type 16
8%
Human Papillomavirus Type 11
8%
Cancer Tissue
8%
Somatic Mutation
8%
Fibroblast
8%
Pharmacology, Toxicology and Pharmaceutical Science
Epstein-Barr Virus
100%
Precancer
100%
Human Papillomavirus
100%
Carcinogenesis
41%
Human Papillomavirus Type 6
33%
Protein P53
16%
Infection
16%
Nude Mouse
16%
Gelatinase A
16%
Mouth Cancer
8%
Human Papillomavirus Type 16
8%
Malignant Transformation
8%
Human Papillomavirus Type 11
8%
Mixed Infection
8%